AIM ImmunoTech (STU:HXB2) Total Liabilities : €10.45 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Total Liabilities?

AIM ImmunoTech's Total Liabilities for the quarter that ended in Mar. 2024 was €10.45 Mil.

AIM ImmunoTech's quarterly Total Liabilities increased from Sep. 2023 (€4.93 Mil) to Dec. 2023 (€8.39 Mil) and increased from Dec. 2023 (€8.39 Mil) to Mar. 2024 (€10.45 Mil).

AIM ImmunoTech's annual Total Liabilities increased from Dec. 2021 (€0.73 Mil) to Dec. 2022 (€1.91 Mil) and increased from Dec. 2022 (€1.91 Mil) to Dec. 2023 (€8.39 Mil).

AIM ImmunoTech Total Liabilities Historical Data

The historical data trend for AIM ImmunoTech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Total Liabilities Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

6.58

2.70

0.73

1.91

8.39

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.31	3.21	4.93	8.39	10.45

AIM ImmunoTech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AIM ImmunoTech's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.934	+	(0.454	+	-2.7755575615629E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.39

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	17.772	-	9.385
	=	8.39

AIM ImmunoTech's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.086	+	(1.368	+	2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	10.45

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	14.894	-	4.44
	=	10.45

AIM ImmunoTech Total Liabilities Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines